Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Duchenne muscular dystrophy (DMD)
Fierce Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.
Angus Liu
Jun 16, 2025 10:58am
RegenXBio links DMD gene therapy to improved outcomes
Jun 5, 2025 8:52am
Keros culls phase 2 PAH program, 70 staff roles
May 29, 2025 10:10am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
Capricor shares turn red as FDA announces deramiocel adcomm plan
May 6, 2025 8:32am
Entrada lays off 20% of staff weeks after having FDA hold lifted
Apr 30, 2025 4:38am
